Bian J T, Bhargava H N
Department of Pharmaceutics and Pharmacodynamics (M/C 865), University of Illinois at Chicago, Health Sciences Center 60612, USA.
Peptides. 1996;17(8):1415-9. doi: 10.1016/s0196-9781(96)00215-x.
The effects of morphine-3-glucuronide (M3G), a metabolite of morphine, were determined on the antinociceptive actions, as measured by the tail flick test, of morphine, a mu-opioid receptor agonist, of U-50,488H, a kappa-opioid receptor agonist of [D-Pen2, D-Pen3]enkephalin (DPDPE), a delta 1-opioid receptor agonist, and of [D-Ala2,Glu4]deltorphin II (deltorphin II), a delta 2-opioid receptor agonist in mice. Morphine administered ICV (2.5 micrograms/ mouse) or SC (10 mg/kg), U-50,488H (25 mg/kg, IP), DPDPE (15 micrograms/mouse; ICV), and deltorphin II (15 micrograms/mouse, ICV) produced antinociception in mice. Intraperitoneal or ICV injections of M3G did not produce any effect on the tail flick latency nor did it affect the antinociception-induced by morphine, U-50,488H, DPDPE, or deltorphin II. Previously M3G has been shown to antagonize the antinociceptive effects of morphine in the rat. It is concluded that in the mouse, M3G neither produces hyperalgesia nor modifies the actions of mu-, kappa-, delta 1-, or delta 2-opioid receptor agonists.
通过甩尾试验测定了吗啡的代谢产物吗啡 -3- 葡萄糖醛酸苷(M3G)对吗啡(一种 μ 阿片受体激动剂)、U -50,488H(一种 κ 阿片受体激动剂)、[D - Pen2,D - Pen3]脑啡肽(DPDPE,一种 δ1 阿片受体激动剂)以及 [D - Ala2,Glu4]强啡肽 II(强啡肽 II,一种 δ2 阿片受体激动剂)在小鼠体内的镇痛作用的影响。脑室内注射(2.5 微克/小鼠)或皮下注射(10 毫克/千克)吗啡、腹腔注射 U -50,488H(25 毫克/千克)、脑室内注射 DPDPE(15 微克/小鼠)以及脑室内注射强啡肽 II(15 微克/小鼠)均可使小鼠产生镇痛作用。腹腔注射或脑室内注射 M3G 对甩尾潜伏期未产生任何影响,也不影响吗啡、U -50,488H、DPDPE 或强啡肽 II 诱导的镇痛作用。此前已表明 M3G 在大鼠中可拮抗吗啡的镇痛作用。得出的结论是,在小鼠中,M3G 既不产生痛觉过敏,也不改变 μ、κ、δ1 或 δ2 阿片受体激动剂的作用。